{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T18:43:52Z","timestamp":1791917032981,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T00:00:00Z","timestamp":1761782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"DOI":"10.1007\/s00432-025-06303-w","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T11:40:18Z","timestamp":1761824418000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Immunotherapy with and without radiotherapy following the diagnosis of bone metastasis for stage IV non-small cell carcinoma"],"prefix":"10.1007","volume":"151","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2606-6366","authenticated-orcid":false,"given":"Jeffrey","family":"Beyon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1195-4630","authenticated-orcid":false,"given":"Jennifer E.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine A.","family":"Welch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,30]]},"reference":[{"key":"6303_CR1","doi-asserted-by":"publisher","first-page":"8435","DOI":"10.1038\/s41467-023-44195-x","volume":"14","author":"NK Altorki","year":"2023","unstructured":"Altorki NK, Walsh ZH, Melms JC et al (2023) Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. Nat Commun 14:8435. https:\/\/doi.org\/10.1038\/s41467-023-44195-x","journal-title":"Nat Commun"},{"key":"6303_CR2","doi-asserted-by":"publisher","first-page":"e70402","DOI":"10.1002\/cam4.70402","volume":"13","author":"JL Burr","year":"2024","unstructured":"Burr JL, Johnson KC, Carmicheal JJ, Lin C, Ganti AK (2024) Combination immunotherapy with radiotherapy in non-small cell lung cancer: a review of evidence. Cancer Med 13:e70402. https:\/\/doi.org\/10.1002\/cam4.70402","journal-title":"Cancer Med"},{"issue":"3","key":"6303_CR3","doi-asserted-by":"publisher","first-page":"e10125","DOI":"10.1002\/jbm4.10125","volume":"3","author":"NM Byrne","year":"2019","unstructured":"Byrne NM, Summers MA, McDonald MM (2019) Tumor cell dormancy and reactivation in bone: skeletal biology and therapeutic opportunities. JBMR plus 3(3):e10125. https:\/\/doi.org\/10.1002\/jbm4.10125","journal-title":"JBMR plus"},{"key":"6303_CR4","unstructured":"Cancer Staging (2022a) Diagnosis and Staging, National Cancer Institute"},{"key":"6303_CR5","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S0140-6736(23)01384-3","volume":"402","author":"JY Chang","year":"2023","unstructured":"Chang JY, Lin SH, Dong W et al (2023) Stereotactic ablative radiotherapy with or without immunotherapy for early-stage or isolated lung parenchymal recurrent node-negative non-small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet 402:871\u2013881. https:\/\/doi.org\/10.1016\/S0140-6736(23)01384-3","journal-title":"Lancet"},{"key":"6303_CR6","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","volume":"8","author":"Z Chen","year":"2023","unstructured":"Chen Z, Han F, Du Y et al (2023) Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions. Sig Transduct Target Ther 8:70. https:\/\/doi.org\/10.1038\/s41392-023-01332-8","journal-title":"Sig Transduct Target Ther"},{"issue":"6","key":"6303_CR7","doi-asserted-by":"publisher","first-page":"a031252","DOI":"10.1101\/cshperspect.a031252","volume":"8","author":"M Esposito","year":"2018","unstructured":"Esposito M, Guise T, Kang Y (2018) The biology of bone metastasis. Cold Spring Harb Perspect Med 8(6):a031252. https:\/\/doi.org\/10.1101\/cshperspect.a031252","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"6303_CR8","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1093\/jnci\/djs629","volume":"105","author":"SC Formenti","year":"2013","unstructured":"Formenti SC, Demaria S (2013) Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer 105(4):256\u2013265. https:\/\/doi.org\/10.1093\/jnci\/djs629","journal-title":"J Natl Cancer"},{"key":"6303_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13014-019-1222-3","volume":"14","author":"CC Foster","year":"2019","unstructured":"Foster CC, Sher DJ, Rusthoven CG, Verma V, Spiotto MT, Weichselbaum RR, Koshy M (2019) Overall survival according to immunotherapy and radiation treatment for metastatic non-small-cell lung cancer: a National Cancer Database analysis. Radiat Oncol 14:18. https:\/\/doi.org\/10.1186\/s13014-019-1222-3","journal-title":"Radiat Oncol"},{"key":"6303_CR10","doi-asserted-by":"publisher","first-page":"1527742","DOI":"10.3389\/or.2025.1527742","volume":"19","author":"S Hazout","year":"2025","unstructured":"Hazout S, Oehler C, Zwahlen DR, Taussky D (2025) Historical view of the effects of radiation on cancer cells. Oncol Rev 19:1527742. https:\/\/doi.org\/10.3389\/or.2025.1527742","journal-title":"Oncol Rev"},{"key":"6303_CR11","unstructured":"Immunotherapy to Treat Cancer. (2019a) Types of Cancer Treatment, National Cancer Institute"},{"key":"6303_CR12","unstructured":"Jayarangaiah A, Kemp AK, Theetha Kariyanna P (2023) Bone Metastasis. In: StatPearls [Online]. StatPearls Publishing, Florida. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK507911\/. Accessed 13 Aug 2025"},{"key":"6303_CR13","doi-asserted-by":"publisher","first-page":"100505","DOI":"10.1016\/j.jbo.2023.100505","volume":"43","author":"GJ Joseph","year":"2023","unstructured":"Joseph GJ, Johnson DB, Johnson RW (2023) Immune checkpoint inhibitors in bone metastasis: clinical challenges, toxicities, and mechanisms. J Bone Oncol 43:100505. https:\/\/doi.org\/10.1016\/j.jbo.2023.100505","journal-title":"J Bone Oncol"},{"key":"6303_CR14","unstructured":"Key Statistics for Lung Cancer (2024) About Lung Cancer, American Cancer Society"},{"key":"6303_CR15","doi-asserted-by":"publisher","first-page":"991431","DOI":"10.3389\/fimmu.2022.991431","volume":"13","author":"S Li","year":"2022","unstructured":"Li S, Chen K, Yang M et al (2022) Radiotherapy improves the outcomes of immunotherapy with Sintilimab in non-small-cell lung cancer: a real-world analysis. Front Immunol 13:991431. https:\/\/doi.org\/10.3389\/fimmu.2022.991431","journal-title":"Front Immunol"},{"key":"6303_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1186\/s12885-020-07055-1","volume":"20","author":"RIY Lieverse","year":"2020","unstructured":"Lieverse RIY, Van Limbergen EJ, Oberije CJG et al (2020) Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, immunosabr: a multicentre, randomised controlled open-label phase II trial. BMC Cancer 20:557. https:\/\/doi.org\/10.1186\/s12885-020-07055-1","journal-title":"BMC Cancer"},{"key":"6303_CR17","doi-asserted-by":"publisher","first-page":"1211815","DOI":"10.3389\/fonc.2023.1211815","volume":"13","author":"X Liu","year":"2023","unstructured":"Liu X, Chi A (2023) Combining stereotactic body radiotherapy with immunotherapy in stage IV non-small cell lung cancer. Front Oncol 13:1211815. https:\/\/doi.org\/10.3389\/fonc.2023.1211815","journal-title":"Front Oncol"},{"key":"6303_CR18","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.21037\/tlcr-22-843","volume":"11","author":"L Liu","year":"2022","unstructured":"Liu L, Yuan M, Ding Z et al (2022) Immunotherapy with radiotherapy fails to improve prognosis of patients with stage IV non-small cell lung cancer: a retrospective cohort analysis of the THUNDER-2 study. Transl Lung Cancer Res 11:2507\u20132520. https:\/\/doi.org\/10.21037\/tlcr-22-843","journal-title":"Transl Lung Cancer Res"},{"key":"6303_CR19","doi-asserted-by":"publisher","first-page":"110048","DOI":"10.1016\/j.radonc.2023.110048","volume":"190","author":"I Popp","year":"2024","unstructured":"Popp I, Vaes RDW, Wieten L et al (2024) Radiotherapy to reinvigorate immunotherapy activity after acquired resistance in metastatic non-small-cell lung cancer: a pooled analysis of two institutions prospective phase II single arm trials. Radiother Oncol 190:110048. https:\/\/doi.org\/10.1016\/j.radonc.2023.110048","journal-title":"Radiother Oncol"},{"key":"6303_CR20","unstructured":"Radiation Therapy to Treat Cancer (2019b) Types of Cancer Treatment, National Cancer Institute"},{"issue":"1","key":"6303_CR21","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.lungcan.2014.07.020","volume":"86","author":"M Riihim\u00e4ki","year":"2014","unstructured":"Riihim\u00e4ki M, Hemminki A, Fallah M, Thomsen H, Sundquist K, Sundquist J, Hemminki K (2014) Metastatic sites and survival in lung cancer. Lung Cancer 86(1):78\u201384. https:\/\/doi.org\/10.1016\/j.lungcan.2014.07.020","journal-title":"Lung Cancer"},{"key":"6303_CR22","unstructured":"Stage 4 lung cancer (2022b) In: Markman M (ed) Stages, City of Hope Cancer Center"},{"key":"6303_CR23","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/S2213-2600(20)30391-X","volume":"9","author":"W Theelen","year":"2021","unstructured":"Theelen W, Chen D, Verma V et al (2021) Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med 9:467\u2013475. https:\/\/doi.org\/10.1016\/S2213-2600(20)30391-X","journal-title":"Lancet Respir Med"},{"key":"6303_CR24","doi-asserted-by":"publisher","first-page":"5188","DOI":"10.1158\/1078-0432.CCR-21-0145","volume":"27","author":"WT Turchan","year":"2021","unstructured":"Turchan WT, Pitroda SP, Weichselbaum RR (2021) Radiotherapy and immunotherapy combinations in the treatment of patients with metastatic disease: current status and future focus. Clin Cancer Res 27:5188\u20135194. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-0145","journal-title":"Clin Cancer Res"},{"key":"6303_CR25","unstructured":"Wilhelm Conrad Roentgen (2014b) In: The Health Consequences of Smoking-50 Years of Progress: A Report of the Surgeon General, Atlanta (GA)"},{"key":"6303_CR26","volume-title":"History of cancer treatments: radiation therapy","author":"Wilhelm Conrad Roentgen","year":"2014","unstructured":"Wilhelm Conrad Roentgen (2014) History of cancer treatments: radiation therapy. American Cancer Society, The History of Cancer"},{"key":"6303_CR27","doi-asserted-by":"publisher","first-page":"786864","DOI":"10.3389\/fmolb.2022.786864","volume":"9","author":"X Zhao","year":"2022","unstructured":"Zhao X, Li J, Zheng L et al (2022) Immune response on optimal timing and fractionation dose for hypofractionated radiotherapy in non-small-cell lung cancer. Front Mol Biosci 9:786864. https:\/\/doi.org\/10.3389\/fmolb.2022.786864","journal-title":"Front Mol Biosci"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06303-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-025-06303-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-025-06303-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T16:52:11Z","timestamp":1766508731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-025-06303-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":27,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6303"],"URL":"https:\/\/doi.org\/10.1007\/s00432-025-06303-w","relation":{},"ISSN":["1432-1335"],"issn-type":[{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,30]]},"assertion":[{"value":"19 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"This study utilized de-identified data obtained from the TriNetX database. The research was conducted in compliance with the ethical principles outlined in the Declaration of Helsinki and adhered to applicable legal and regulatory requirements. A waiver of informed consent was granted as the research involves no risk to participants, does not adversely affect their rights or welfare, and could not be practicably carried out without the waiver. The data used in this study was de-identified in accordance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule (45 CFR \u00a7164.514). The de-identification process was certified by a qualified expert, ensuring the confidentiality and privacy of all participants. This study was exempt from Institutional Review Board (IRB) oversight, as it involved the secondary analysis of pre-existing, de-identified data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"As this study utilized de-identified data from the TriNetX database, a waiver of informed consent was obtained in accordance with ethical guidelines and regulatory requirements. The waiver was approved based on the following criteria: The research involves no more than minimal risk to participants. The waiver does not adversely affect the rights and welfare of participants. The research could not practicably be carried out without the waiver. The study does not involve direct interaction with participants, and all data is de-identified in compliance with the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule (45 CFR \u00a7164.514). As a result, no individual consent was required or sought for this research.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"309"}}